US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
ASE Test, Inc., a ten percent owner of Ainos Inc. (NASDAQ:AIMD), acquired 29,476 shares of common stock on June 23, 2025. The shares were purchased at a price of approximately $0.497 per share, for a total value of $14,649.57. The transaction increased ASE Test, Inc.’s direct holdings in Ainos, Inc. to 58,887 shares. The micro-cap company, currently valued at $10.4 million, has shown significant volatility with a beta of 2.22 and a steep 39% decline over the past year. According to InvestingPro analysis, the stock’s financial health score is rated as WEAK.
The acquisition was made pursuant to a Share Exchange Agreement between ASE Test and Taiwan Carbon Nano Technology Corporation, in exchange for 5,687,109 ordinary shares of Ainos Inc., a Cayman Islands company.
Alan Li, authorized signatory of ASE Test, Inc., and Joseph Tung, authorized signatory of ASE Technology Holding Co (NYSE:ASX)., Ltd., signed the Form 4 on June 25, 2025.
In other recent news, Ainos, Inc. reported its first revenue from AI Nose technology deployments in Japan’s senior care sector, with a notable 412% increase in Q1 revenue year-over-year. The company has also received regulatory approval in Taiwan to initiate human clinical trials for its VELDONA oral interferon treatment targeting HIV-related oral warts and primary Sjögren’s syndrome, with patient enrollment expected in the latter half of 2025. In a strategic move, Ainos has partnered with Kenmec Mechanical Engineering Co., Ltd. to scale its AI smell detection technology for industrial applications, providing Kenmec with a commercial license to deploy AI Nose in automation solutions. Ainos is also collaborating with ugo, Inc., a Japanese robotics company, to integrate its smell detection technology into service robots, marking a significant advancement in robotics and AI. This collaboration aims to enhance robots’ ability to perceive their environment through smell, potentially transforming service robotics. Furthermore, Ainos has reported progress in its AI Nose platform’s accuracy in elder care scent detection, improving to 85% from a previous 80%. The company plans to expand its smell identification capabilities to classify everyday scents, with preliminary accuracy exceeding 90%. These developments reflect Ainos’ ongoing efforts to innovate and expand the applications of its AI Nose technology across various sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.